sNfL test useful for assessing disease severity and monitoring treatment, new study shows

Researchers have established what they believe to be a clinically relevant threshold for the serum neurofilament light chain (sNfL) test, paving the way for its future implementation in routine practice.

The test is widely used in clinical trials and has been shown to be linked to disease activity, predicting long-term clinical and imaging outcomes. Levels of SNfL have also been shown to be reduced by the use of disease-modifying therapies.

The test measures serum levels of neurofilaments that are released after axonal damage.

At ECTRIMS, Dr Peter Calabresi of Johns Hopkins Hospital in Baltimore, Maryland, USA, presented data from a study assessing the SIMOA assay for sNfL. The study collected data from four clinical trials, involving more than 1,000 patients with relapsing-remitting MS.

Want to read more?

Log in or sign up to access all Neurodiem content.

Already have an account? Log In

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.